Avadel Pharmaceuticals PLC (AVDL): Price to Sales

Symbol and logo of brand Avadel Pharmaceuticals PLC (AVDL)

The premium positioning of Lumryz provides Avadel Pharmaceuticals (AVDL) with strong pricing power. The current P/S multiple reflects market expectations, with the value holding at 8.50. The business relies on insurance reimbursements for its innovative narcolepsy therapy. High macro-resilience and a lack of seasonality make the company's revenue independent of economic crises.

Market Cap to Revenue: avadel.com (AVDL) for 08/13/2023 - 02/28/2026

Analytical breakdowns for Avadel Pharma (AVDL)

- share price and consensus valuation forecast:
Price Performance Chart avadel.com|AVDL - Price Target Chart
- stock exchange capitalization data:
Market Value Avadel Pharma|AVDL - Enterprise Value
- shareholders' equity book value data:
Book Value per Share Avadel Pharmaceuticals|AVDL - Company Net Assets|Market Value to Book Value Ratio avadel.com|AVDL - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Avadel Pharmaceuticals|AVDL - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Avadel Corp|AVDL - Company Aggregate Debts|Debts to Book Value Avadel Pharma|AVDL - Company Long-Term Debt|Company Short-Term Debt Avadel Pharmaceuticals|Intermediate Coverage Ratio avadel.com
- company profitability and valuation multiples indicators:
AVDL - Company Net Income|Forward Earnings Avadel Pharmaceuticals|AVDL - P/E Multiple|Future Price to Earnings Multiple Avadel Pharmaceuticals PLC|AVDL - PEG Multiple|EV/EBITDA Multiple Avadel Pharma|AVDL - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Avadel Pharmaceuticals|AVDL - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months avadel.com|AVDL - Earnings growth in current year|Earnings growth forecast for next year Avadel Pharmaceuticals
- sales revenue and business income indicators:
AVDL - Revenue and Sales Volume|Company Future Sales Volume avadel.com|AVDL - P/S Multiple|Market Cap to Future Revenue Ratio Avadel Pharma
General company analysis:AVDL - avadel.com
Signature product of avadel.com

Identifying fundamentally resilient assets requires analyzing the ratio of a business's market value to its annual revenue. This price-to-sales multiple determines the price of each unit of sales, which for Avadel Pharmaceuticals (AVDL) confirms a premium valuation due to the exclusivity of its narcolepsy drug patent and guaranteed demand, reflecting the real-time value dynamics shown in this chart.

Competitors of Avadel Pharmaceuticals

ALKS (alkermes.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio atai Life Sciences ATAI|GH Research plc (GHRS) - Price to Sales|MindMed Inc. - P/S Multiple|CMPS - P/S Multiple|LBRX (LB Pharmaceuticals Inc) - Market Cap to Revenue|DRUG (brightmindsbio.com) - Price-to-Revenue Ratio|VNDA (Vanda Pharmaceuticals Inc.) - P/S Multiple|P/S Multiple Cybin Corp|P/S Multiple ANRO|NRx Pharmaceuticals, Inc - Market Cap to Revenue Ratio|P/S Multiple CING (Cingulate)|Silo Pharma Inc. (SILO) - Price to Sales|CPHI - Price-to-Revenue Ratio|CMND: Price-to-Revenue Ratio|PBM (Psyence Biomedical Limited) - Market Cap to Revenue|SciSparc Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Seelos Therapeutics|Virpax - Price-to-Sales Ratio|P/S Multiple KRTX